 The purchase was subsequently completed for the announced price on October 3, 2017.Following the sale of Kite to Gilead, Kite's founders and its CMO struck a deal in February 2018 with Pfizer to develop CAR-T therapeutics, leading to the creation of Allogene Therapeutics.The three former Kite executives subsequently hired into Allogene a number of people who left Kite after its sale.